Lp - PLA2 is an enzyme secreted by macrophages. It's in the blood when there is no stable plaque. Hypertension, metabolic syndrome are risk factors of metabolic cardiovascular disease. Quantitative Lp-PLA2 has extremely important implications for risk prediction in patients with vascular disease, especially hypertension and hypertensive patients with metabolic syndrome.Design and Method:
It was a cross-sectional descriptive method controlled. We conducted over 80 patients with hypertension, Among them 50 hypertensive patients with metabolic syndrome, 30 control patients with lone hypertension.Results:
Lp-PLA2 increased in patients with hypertension than hypertension alone (p < 0.05). The concentration of Lp - PLA2 in hypertensive patients with metabolic syndrome was 46.92 ± 8.06 IU / ml. and in patients with hypertension alone was14.04 ± 1.1 IU / ml. There was a correlation between Lp - PLA2 with blood pressure (r = 0.46), blood glucose (r = 0.34), total cholesterol (r = 0.72), triglyceride (r = 0.67), HDL - C (r = -0.76), LDL – C (r = 0.58), hs - CRP (r = 0.64), BMI (r = 0.56) particularly with Framingham score (r = 0.85).Sensitivity, specificity of Lp - PLA2 in the diagnosis of metabolic syndrome is quite high with an area under the ROC curve: 0.886 and CI: 0.788 to 0.924.Conclusions:
Lp - PLA2 is a new predictor in hypertension with metabolic syndrome which was considered as a risk of cardiovascular disease.